A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer by Haiman, CA et al.
This is a repository copy of A common variant at the TERT-CLPTM1L locus is associated 
with estrogen receptor-negative breast cancer.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/152414/
Version: Accepted Version
Article:
Haiman, CA, Chen, GK, Vachon, CM et al. (128 more authors) (2011) A common variant at
the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. 
Nature Genetics, 43 (12). 1210. ISSN 1061-4036 
https://doi.org/10.1038/ng.985
© 2011 Nature America, Inc. This is an author-produced version of a paper subsequently 
published in Nature Genetics. Uploaded in accordance with the publisher's self-archiving 
policy.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
A common variant at the TERT-CLPTM1L locus is associated
with estrogen receptor–negative breast cancer
Christopher A Haiman1, Gary K Chen1, Celine M Vachon2, Federico Canzian3, Alison
Dunning4, Robert C Millikan5, Xianshu Wang6, Foluso Ademuyiwa7, Shahana Ahmed4,
Christine B Ambrosone8, Laura Baglietto9, Rosemary Balleine10, Elisa V Bandera11,
Matthias W Beckmann12, Christine D Berg13, Leslie Bernstein14, Carl Blomqvist15, William
J Blot16,17, Hiltrud Brauch18,19, Julie E Buring20, Lisa A Carey21, Jane E Carpenter22, Jenny
Chang-Claude23, Stephen J Chanock24, Daniel I Chasman20, Christine L Clarke22, Angela
Cox25, Simon S Cross26, Sandra L Deming16, Robert B Diasio27, Athanasios M
Dimopoulos28, W Ryan Driver29, Thomas Dünnebier30, Lorraine Durcan31, Diana Eccles31,
Christopher K Edlund1, Arif B Ekici32, Peter A Fasching12,33, Heather S Feigelson34, Dieter
Flesch-Janys35, Florentia Fostira36, Asta Försti37,38, George Fountzilas39, Susan M Gerty31,
The Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium40,
Graham G Giles9, Andrew K Godwin41, Paul Goodfellow42, Nikki Graham31, Dario Greco43,
Ute Hamann30, Susan E Hankinson44,45, Arndt Hartmann46, Rebecca Hein23, Judith
Heinz35, Andrea Holbrook1, Robert N Hoover24, Jennifer J Hu47, David J Hunter45,48, Sue A
Ingles1, Astrid Irwanto49, Jennifer Ivanovich42, Esther M John50,51, Nicola Johnson52, Arja
Jukkola-Vuorinen53, Rudolf Kaaks54, Yon-Dschun Ko55, Laurence N Kolonel56, Irene
Konstantopoulou36, Veli-Matti Kosma57, Swati Kulkarni58, Diether Lambrechts59,60, Adam
M Lee27, Loïc Le Marchand56, Timothy Lesnick2, Jianjun Liu49, Sara Lindstrom45,48, Arto
Mannermaa61,62, Sara Margolin63, Nicholas G Martin64, Penelope Miron65, Grant W
Montgomery64, Heli Nevanlinna43, Stephan Nickels23, Sarah Nyante5, Curtis Olswold2,
Julie Palmer66, Harsh Pathak67, Dimitrios Pectasides68, Charles M Perou69, Julian Peto70,
Paul D P Pharoah4, Loreall C Pooler1, Michael F Press71, Katri Pylkäs72, Timothy R
Rebbeck73, Jorge L Rodriguez-Gil47, Lynn Rosenberg66, Eric Ross74, Thomas Rüdiger75,
Isabel dos Santos Silva70, Elinor Sawyer76, Marjanka K Schmidt77, Rüdiger Schulz-
Wendtland46, Fredrick Schumacher1, Gianluca Severi9, Xin Sheng1, Lisa B Signorello16,17,
Hans-Peter Sinn78, Kristen N Stevens2, Melissa C Southey79, William J Tapper31, Ian
Tomlinson80, Frans B L Hogervorst81, Els Wauters59,60, JoEllen Weaver67, Hans Wildiers82,
© 2011 Nature America, Inc. All rights reserved.
Correspondence should be addressed to C.A.H. (haiman@usc.edu) or F.J.C. (couch.fergus@mayo.edu).
40A full list of members is provided in the supplementary Note.
AUTHOR CONTRIBUTIONS
Conceived of and designed the experiments: C.A.H. and F.J.C. Performed the experiments and analyzed the data: C.A.H., L.C.P.,
D.V.D.B., X.S., G.K.C., A. Holbrook, P.W., F.C., D.O.S., X.W., T.L., C.O., K.N.S., A.M.L., L.Y.X., S.L.S. and C.M.V. Contributed
reagents, materials, analysis tools or comments on the manuscript: C.A.H., C.M.V., A.D., R.C.M., X.W., F.A., S.A., C.B.A., L.
Baglietto, R.B., E.V.B., M.W.B., C.D.B., L. Bernstein, C.B., W.J.B., H.B., J.E.B., L.A.C., J.E.C., J.C.-C., S.J.C., D.I.C., C.L.C., A.C.,
S.S.C., S.L.D., R.B.D., A.M.D., W.R.D., T.D., L.D., D.E., C.K.E., A.B.E., P.A.F., H.S.F., D.F.-J., F.F., A.F., G.F., S.M.G., G.G.G.,
A.K.G., P.G., N.G., D.G., U.H., S.E.H., A. Hartmann, R.H., J.H., R.N.H., J.J.H., D.J.H., S.A.I., A.I., J.I., E.M.J., N.J., A.J.-V., R.K.,
Y.-D.K., L.N.K., I.K., V.-M.K., S.K., D.L., A.M.L., L.L.M., T.L., J.L., S.L., A.M., S.M., N.G.M., P.M., G.W.M., H.N., S. Nickels, S.
Nyante, C.O., J. Palmer, H.P., D.P., C.M.P., J. Peto, P.D.P.P., L.C.P., M.F.P., K.P., T.R.R., J.L.R.-G., L.R., E.R., T.R., I.d.S.S., E.S.,
M.K.S., R.S.-W., F.S., G.S., X.S., L.B.S., H.-P.S., K.N.S., M.C.S., W.J.T., I.T., F.B.L.H., E.W., J.W., H.W., R.W., D.Y., W.Z.,
R.G.Z., A.S., S.L.S., D.O.S., D.E., P.K., B.E.H. and F.J.C. Wrote the paper: C.A.H. and F.J.C.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.
Note: Supplementary information is available on the Nature Genetics website.
NIH Public Access
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2012 December 1.
Published in final edited form as:
Nat Genet. ; 43(12): 1210–1214. doi:10.1038/ng.985.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Robert Winqvist72, David Van Den Berg1, Peggy Wan1, Lucy Y Xia1, Drakoulis
Yannoukakos36, Wei Zheng16, Regina G Ziegler24, Afshan Siddiq83, Susan L Slager2,
Daniel O Stram1, Douglas Easton4, Peter Kraft45,48,84, Brian E Henderson1, and Fergus J
Couch2,6
1Department of Preventive Medicine, Keck School of Medicine, University of Southern California/
Norris Comprehensive Cancer Center, Los Angeles, California, USA 2Department of Health
Sciences Research, Mayo Clinic, Rochester, Minnesota, USA 3Genomic Epidemiology Group,
DKFZ, Heidelberg, Germany 4Centre for Cancer Genetic Epidemiology, Strangeways Laboratory,
Worts Causeway, Cambridge, UK 5Lineberger Comprehensive Cancer Center, University of
North Carolina, Chapel Hill, North Carolina, USA 6Department of Laboratory Medicine and
Pathology, Mayo Clinic, Rochester, Minnesota, USA 7Department of Medicine, Roswell Park
Cancer Institute, Buffalo, New York, USA 8Department of Cancer Prevention and Control,
Roswell Park Cancer Institute, Buffalo, New York, USA 9Cancer Epidemiology Centre, The
Cancer Council Victoria & Centre for Molecular, Environmental, Genetic, and Analytic
Epidemiology, The University of Melbourne, Victoria, Australia 10Department of Translational
Oncology, Westmead Hospital, Western Sydney Local Health Network, Westmead, New South
Wales, Australia 11The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
12Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander
University Erlangen-Nuremberg, Erlangen, Germany 13Division of Cancer Prevention, National
Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA 14Division of Cancer
Etiology, Department of Population Science, Beckman Research Institute, City of Hope,
California, USA 15Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
16Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville,
Tennessee, USA 17International Epidemiology Institute, Rockville, Maryland, USA 18Dr.
Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany 19University of
Tübingen, Tübingen, Germany 20Division of Preventive Medicine, Brigham and Women’s
Hospital, Boston, Massachusetts, USA 21Department of Medicine, Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA 22Australian Breast
Cancer Tissue Bank, University of Sydney at the Westmead Millennium Institute, Westmead,
New South Wales, Australia 23Division of Cancer Epidemiology, German Cancer Research
Center, Heidelberg, Germany 24Division of Cancer Epidemiology and Genetics, National Cancer
Institute, US National Institutes of Health, Bethesda, Maryland, USA 25Institute for Cancer
Studies, Department of Oncology, Faculty of Medicine, Dentistry & Health, University of Sheffield,
Sheffield, UK 26Academic Unit of Pathology, Department of Neuroscience, Faculty of Medicine,
Dentistry & Health, University of Sheffield, Sheffield, UK 27Department of Pharmacology, Mayo
Clinic, Rochester, Minnesota, USA 28Department of Clinical Therapeutics, “Alexandra” Hospital,
University of Athens School of Medicine, Athens, Greece 29Epidemiology Research Program,
American Cancer Society, Atlanta, Georgia, USA 30Molecular Genetics of Breast Cancer, DKFZ,
Heidelberg, Germany 31Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton,
UK 32Institute of Human Genetics, Friedrich-Alexander University of Erlangen-Nuremberg,
Erlangen, Germany 33Department of Medicine, Division of Hematology and Oncology, David
Geffen School of Medicine, University of California–Los Angeles, Los Angeles, California, USA
34Kaiser Permanente Colorado, Denver, Colorado, USA 35Institute for Medical Biometrics and
Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg, Germany 36Molecular Diagnostics
Laboratory Institute of Radioisotopes and Radiodiagnostic Products, National Centre for Scientific
Research “Demokritos”, Athens, Greece 37Division of Molecular Genetic Epidemiology, DKFZ,
Heidelberg, Germany 38Center for Primary Health Care Research, University of Lund, Malmö,
Sweden 39Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou
Hospital, Thessaloniki, Greece 41Department of Pathology and Laboratory Medicine, Kansas
University Medical Center, Lawrence, Kansas, USA 42Washington University School of Medicine,
Haiman et al. Page 2
Nat Genet. Author manuscript; available in PMC 2012 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Barnes-Jewish Hospital and Siteman Cancer Center, St. Louis, Missouri, USA 43Department of
Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland 44Channing
Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical
School, Boston, Massachusetts, USA 45Department of Epidemiology, Harvard School of Public
Health, Boston, Massachusetts, USA 46Institute of Pathology, University Hospital Erlangen,
Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany 47Sylvester
Comprehensive Cancer Center and Department of Epidemiology and Public Health, University of
Miami Miller School of Medicine, Miami, Florida, USA 48Program in Molecular and Genetic
Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA 49Human Genetics
Division, Genome Institute of Singapore, Singapore 50Cancer Prevention Institute of California,
Fremont, California 51Stanford University School of Medicine and Stanford Cancer Center,
Stanford, California, USA 52Breakthrough Breast Cancer Research Centre, The Institute of
Cancer Research, London, UK 53Department of Oncology, Oulu University Hospital, University of
Oulu, Oulu, Finland 54Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany
55Department of Internal Medicine, Evangelische Kliniken Johanniter- und Waldkrankenhaus
Bonn gGmbH, Bonn, Germany 56Epidemiology Program, Cancer Research Center, University of
Hawaii, Honolulu, Hawaii, USA 57Department of Pathology, Imaging Centre, Kuopio University
Hospital, Kuopio, Finland 58Department of Surgical Oncology, Roswell Park Cancer Institute,
Buffalo, New York, USA 59Vesalius Research Center, Vlaams Instituut voor Biotechnologie,
Leuven, Belgium 60Vesalius Research Center, University of Leuven, Leuven, Belgium 61Institute
of Clinical Medicine, Department of Pathology, University of Eastern Finland Biocenter Kuopio,
Kuopio, Finland 62Department of Pathology, Imaging Centre, Kuopio University Hospital, Kuopio,
Finland 63Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
64Queensland Institute of Medical Research (QIMR) Genome-Wide Association Study Collective,
Brisbane, Queensland, Australia 65Dana-Farber Cancer Institute, Boston, Massachusetts, USA
66Slone Epidemiology Center at Boston University, Boston, Massachusetts, USA 67Department of
Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA 68Department of
Internal Medicine, Oncology Section, “Hippokration” Hospital, Athens, Greece 69Departments of
Genetics and Pathology, Lineberger Comprehensive Cancer Center, The University of North
Carolina, Chapel Hill, North Carolina, USA 70Department of Epidemiology and Population Health,
London School of Hygiene and Tropical Medicine, London, UK 71Department of Pathology, Keck
School of Medicine and Norris Comprehensive Cancer Center, University of Southern California,
Los Angeles, California 72Laboratory of Cancer Genetics, Department of Clinical Genetics and
Biocenter Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland 73University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA 74Department of Biostatistics,
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA 75Institute of Pathology, Städtisches
Klinikum Karlsruhe, Karlsruhe, Germany 76National Institute for Health Research Comprehensive
Biomedical Research Centre, Guy’s & St. Thomas’ National Health Service Foundation Trust,
London, UK 77Division of Experimental Therapy and Molecular Pathology and Division of
Epidemiology, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The
Netherlands 78Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
79Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne,
Melbourne, Victoria, Australia 80Wellcome Trust Centre for Human Genetics and Oxford
Biomedical Research Centre, University of Oxford, Oxford, UK 81Family Cancer Clinic,
Netherlands Cancer Institut–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
82Multidisciplinary Breast Center, University Hospital Gasthuisberg, Leuven, Belgium 83Imperial
College, London, UK 84Department of Biostatistics, Harvard School of Public Health, Boston,
Massachusetts, USA
Abstract
Haiman et al. Page 3
Nat Genet. Author manuscript; available in PMC 2012 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Estrogen receptor (ER)-negative breast cancer shows a higher incidence in women of African
ancestry compared to women of European ancestry. In search of common risk alleles for ER-
negative breast cancer, we combined genome-wide association study (GWAS) data from women
of African ancestry (1,004 ER-negative cases and 2,745 controls) and European ancestry (1,718
ER-negative cases and 3,670 controls), with replication testing conducted in an additional 2,292
ER-negative cases and 16,901 controls of European ancestry. We identified a common risk variant
for ER-negative breast cancer at the TERT-CLPTM1L locus on chromosome 5p15 (rs10069690:
per-allele odds ratio (OR) = 1.18 per allele, P = 1.0 × 10ᙐ10). The variant was also significantly
associated with triple-negative (ER-negative, progesterone receptor (PR)-negative and human
epidermal growth factor-2 (HER2)-negative) breast cancer (OR = 1.25, P = 1.1 × 10ᙐ9),
particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10ᙐ9). Our results
identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in
multiple populations.
Compared to women of European ancestry, women of African descent are more likely to be
diagnosed with ER-negative breast cancer1. ER-negative tumors and triple-negative tumors
are observed at even higher rates among African women currently residing in Africa2,
suggesting a genetic component to the high risk of ER-negative phenotypes in women of
African descent. Similarly, ER-negative breast cancers and triple-negative breast cancers are
also the predominant histological subtypes in women with germline mutations in BRCA1
(ref. 3). The enrichment for ER-negative disease in this genetically predisposed population
also suggests the existence of additional genetic factors that contribute to the risk of ER-
negative disease. Support for the presence of these factors was recently provided by a
GWAS of breast cancer in BRCA1 mutation carriers, in which a common risk variant for
ER-negative breast cancer on chromosome 19p13 was identified that also was significantly
associated with ER-negative and triple-negative disease in the general population4.
To search for genetic risk factors for ER-negative breast cancer phenotypes, we combined
results from a GWAS of breast cancer in African-American women (African American
Breast Cancer Consortium (AABC): 3,016 cases (1,004 with ER-negative disease) and
2,745 controls) with results from a GWAS of triple-negative breast cancer in women of
European ancestry (Triple-Negative Breast Cancer Consortium (TNBCC): 1,718 cases and
3,670 controls). Genotyping in AABC was conducted with the Illumina Infinium 1M Duo.
In TNBCC, cases were genotyped with the Illumina 660W array, a subset of cases from the
Mammary Carcinoma Risk Factor Investigation (MARIE) component were genotyped using
the Illumina CNV370 SNP array, and cases and controls from the Helsinki Breast Cancer
Study (HEBCS) component were genotyped using the Illumina 550-Duo SNP array.
Genotypes of TNBCC cases were compared with GWAS data for publicly available controls
(Online Methods). Both studies imputed genotypes for common SNPs in phase 2 HapMap
populations (release 21) (Supplementary Table 1 and Online Methods). A total of 3,154,485
SNPs, genotyped and imputed, were analyzed in stage 1 of the meta-analysis.
We observed little evidence of inflation in the test statistics in AABC (Ȝ = 1.01) or TNBCC
(Ȝ = 1.04) or in the meta-analysis of the two GWAS (Ȝ = 1.02; Supplementary Fig. 1). In the
combined results, only SNP rs10069690 (NCBI36/hg18, chr5:1,332,790) located in intron 4
of the TERT gene (encoding telomerase reverse transcriptase) at chromosome 5p15 showed
a genome-wide significant association with ER-negative breast cancer (AABC: OR per
allele = 1.32, P = 1.3 × 10ᙐ6; TNBCC: OR = 1.25, P = 1.2 × 10ᙐ3; combined OR = 1.29, P
= 1.0 × 10ᙐ8). Whereas SNP rs10069690 was genotyped in AABC, it was imputed in
TNBCC (R2 = 0.55). To verify the imputed genotypes and the significance of the association
in TNBCC, we re-genotyped rs10069690 in available DNA samples from 2,963 TNBCC
cases and 1,632 study-specific TNBCC controls (Online Methods). Although the
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overlapping samples between the TNBCC GWAS and the re-genotyping study showed that
the quality of imputation for rs10069690 in the GWAS was poor (Online Methods), the
association with ER-negative breast cancer for rs10069690 remained statistically significant
in the larger re-genotyped TNBCC sample (OR = 1.18, P = 1.0 × 10ᙐ3; Table 1 and Fig. 1)
and in the new combined results for AABC and the re-genotyped TNBCC sample (OR =
1.24, P = 1.6 × 10ᙐ8).
To further confirm the association at 5p15, we genotyped SNP rs10069690 in women of
European ancestry, which included 8,365 cases (1,359 ER negative) and 10,935 controls
from the US National Cancer Institute Breast and Prostate Cancer Cohort Consortium
(BPC3) and 6,182 cases (933 ER negative) and 5,966 controls from Studies of
Epidemiology and Risk Factors in Cancer Heredity (SEARCH). Evidence for replication
was observed for rs10069690 and ER-negative breast cancer in both studies (BPC3: OR =
1.09, P = 0.077; SEARCH: OR = 1.21, P = 6.9 × 10ᙐ4; Table 1).
In combining the results across all studies (6,009 ER-negative cases and 20,708 controls
with genotype data), rs10069690 was significantly associated with an increased risk of ER-
negative breast cancer (OR = 1.18, 95% confidence interval (CI), 1.13–1.25; P = 1.0 ×
10ᙐ10; Table 1). The risk for heterozygote and homozygote carriers was 1.15 (95% CI, 1.06–
1.23) and 1.46 (95% CI, 1.29–1.64), respectively. We observed little evidence of
heterogeneity for the reported association for this variant by study or country in AABC (test
for heterogeneity, phet = 0.86), TNBCC (phet = 0.85) or BPC3 (phet = 0.37; Supplementary
Table 2).
In an analysis of ER-positive cases, rs10069690 was only weakly associated with risk in
African Americans (AABC: 1,558 ER-positive cases and 2,743 controls with genotype data,
OR = 1.08, P = 0.10) and in women of European ancestry (BPC3: 4,890 ER-positive cases
and 10,397 controls, OR = 1.03, P = 0.31; SEARCH: 3,534 ER positive cases and 5,966
controls, OR = 1.03, P = 0.37; combined for all populations: OR = 1.04, P = 0.06, phet =
0.64). The statistical power to detect an OR of 1.18 (observed for ER-negative disease) for
ER-positive disease was >99% in the combined sample (9,982 cases and 19,106 controls),
assuming the risk allele frequency of 0.26 in people of European decent. This result suggests
that the association with breast cancer might be specific for ER-negative subtypes (P value
for case-only test of ER negative versus ER positive = 1.7 × 10ᙐ4).
We further stratified the cases by HER2 status to assess whether this region may be a risk
locus for triple-negative disease. In AABC, BPC3 and SEARCH the association with
rs10069690 was greater for triple-negative tumors than for ER-negative, PR-negative,
HER2-positive tumors (Table 2), and, in combining all studies, including TNBCC, the
association with rs10069690 was significantly greater for triple-negative disease (3,707
triple-negative cases and 19,728 controls with genotype data, OR = 1.25, P = 1.1 × 10ᙐ9;
376 ER-negative, PR-negative, HER2-positive cases and 18,126 controls, OR = 1.03, P =
0.71; P value for case-only test = 0.010). The association with rs10069690 was also
observed to be significantly greater for ER-negative and triple-negative disease at younger
ages (<50 years: ER negative, OR = 1.32, P = 1.4 × 10ᙐ8; triple negative, OR = 1.48, P =
1.9 × 10ᙐ9; P for interaction with age = 0.035 and 3.2 × 10ᙐ3, respectively; Supplementary
Table 3). We found no significant association with rs1006960 among ER- and PR-positive
cases when stratified by HER2 status (513 triple-positive cases and 18,126 controls, OR =
1.09, P = 0.21; 2,808 ER-positive, PR-positive, HER2-negative cases and 18,126 controls,
OR = 1.04, P = 0.29), which suggests the association may be limited to triple-negative
disease and not all HER2-negative tumors.
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Similar to 8q24 (refs. 5–7) and 11q13 (refs. 8–10), the TERT-CLPTM1L locus harbors
multiple risk variants for different cancers (reviewed in ref. 11). SNP rs10069690 is
modestly correlated (r2 = 0.13–0.43 in 1000 Genomes Project populations of European and
African ancestry, Supplementary Fig. 2) with variants found for serous ovarian cancer
(rs7726159), glioma (rs2736100) and lung cancer (rs2736100, rs2735940)12–14. Aside from
risk variant rs2853676 found for glioma14, which we found to be associated with risk in
TNBCC (P = 0.014, r2 = 0.05 with rs10069690), none of the known risk variants identified
for other cancers in the TERT-CLPTM1L region was significantly associated with breast
cancer risk in TNBCC or AABC. Although rs7726159 was not tested in AABC or TNBCC
(as it is not on the Illumina arrays or in HapMap), it is noteworthy that the first common risk
variant identified for ER-negative breast cancer, at chromosome 19p13, is also associated
with risk for serous ovarian cancer15. The TERT gene encodes the catalytic subunit of
telomerase, which controls telomere length, a process linked with genomic instability and
implicated in tumorigenesis. Sequencing of the coding exons of TERT in 96 African-
American women (Online Methods) did not reveal a coding variant strongly correlated with
rs10069690. The TERT locus may highlight another biological process common to the
pathogenesis of ER-negative breast cancer subtypes and serous ovarian cancer that is also
shared with other cancers.
Identification of the variant directly responsible for the association will be required to fully
address the extent to which this locus contributes to the greater incidence of ER-negative
and triple-negative tumors in women of African ancestry. However, it is notable that the risk
allele frequency of rs10069690 is greater in African American women (frequency, 0.57)
than in women of European ancestry (frequency, 0.26). If this variant is an equally good
surrogate for the biologically functional allele in each population, then this locus may be
responsible for a 15% (95% CI, 10–20%) higher incidence rate of ER-negative or triple-
negative breast cancer in women of African compared to European ancestry (Online
Methods). Larger studies with well-characterized tumor pathology information will be
needed to determine whether the association we observed applies to all ER-negative disease
or just the triple-negative subtype. Our findings provide further support for the presence of
genetic susceptibility to ER-negative breast cancer subtypes and demonstrate the importance
of discovery efforts in multiple populations.
METHODS
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturegenetics/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
A regional plot of the –log10 P values for SNPs at the chromosome 5p15 risk locus from the
meta-analysis of the AABC and TNBCC stage 1 studies. SNP rs10069690 is designated
with the purple diamonds. The colors depict the strength of the correlation (r2) between SNP
rs10069690 and the SNPs tested in the region. The correlation is estimated using 1000
Genomes Project (1KGP) data for the HapMap CEU population (June 2010). Squares are
SNPs that were genotyped in AABC and TNBCC. Circles are SNPs that were genotyped in
one study and imputed in the other or imputed in both studies. The blue line indicates the
recombination rates in centimorgans (cM) per megabase (Mb). Also shown are the SNP
Build 36 coordinates and genes in the region.
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Table 1
Association of rs10069690 at 5p15 and ER-negative breast cancer risk
Stage Consortium or study Cases/controlsa RAFb T allele Heterozygotes OR (95% CI)c Homozygotes OR (95% CI)c Per-allele OR (95% CI)c P value (1-d.f.)d
1 AABC 1,002/2,743 0.57 1.32 (1.05–1.67) 1.74 (1.37–2.21) 1.32 (1.18–1.48) 1.3 × 10ᙐ6
1 TNBCC 2,785/1,602 0.27 1.10 (0.97–1.26) 1.53 (1.21–1.95) 1.18 (1.07–1.30) 1.0 × 10ᙐ3
2 BPC3 1,289/10,397 0.26 1.08 (0.96–1.22) 1.19 (0.95–1.49) 1.09 (0.99–1.19) 0.077
2 SEARCH 933/5,966 0.26 1.23 (1.06–1.43) 1.44 (1.10–1.89) 1.21 (1.09–1.36) 6.9 × 10ᙐ4
Combined 6,009/20,708 1.15 (1.06–1.23) 1.46 (1.29–1.64) 1.18 (1.13–1.25) 1.0 × 10ᙐ10
aNumber of cases and controls with genotype data for rs10069690. All subjects were directly genotyped.
b
Risk allele frequency (RAF) in controls.
cAdjusted for age, study and principal components in AABC. Adjusted for age and country in TNBCC. Adjusted for age, study and country (European Prospective Investigation into Cancer and Nutrition
(EPIC) only) in BPC3. Adjusted for age in SEARCH. Combined results are from the meta-analysis.
d
P for trend (one degree of freedom (1-d.f.)).
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Table 2
Association of rs10069690 at 5p15 stratified by Her2 status
Consortium or study Subtype Cases/controlsa Heterozygotes OR (95% CI)b Homozygotes OR (95% CI)b Per-allele OR (95% CI)b P value (1-d.f.)c Case-only P
AABCd ERᙐPRᙐHER2ᙐ 440/2,407 1.35 (0.97–1.89) 1.78 (1.27–2.49) 1.33 (1.14–1.55) 3.0 × 10ᙐ4 0.19
ERᙐPRᙐHER2+ 115/2,407 1.83 (0.99–3.40) 1.59 (0.82–3.05) 1.15 (0.86–1.52) 0.34
TNBCC ERᙐPRᙐHER2ᙐ 2,785/1,602 1.10 (0.97–1.26) 1.53 (1.21–1.95) 1.18 (1.07–1.30) 1.0 × 10ᙐ3 –
BPC3e ERᙐPRᙐHER2ᙐ 300/9,753 1.19 (0.93–1.52) 1.64 (1.10–2.46) 1.25 (1.04–1.49) 0.015 0.13
ERᙐPRᙐHER2+ 198/9,753 0.99 (0.73–1.33) 0.95 (0.53–1.70) 0.98 (0.78–1.23) 0.87
SEARCH ERᙐPRᙐHER2ᙐ 182/5,966 1.42 (1.03–1.95) 2.41 (1.47–3.95) 1.51 (1.20–1.89) 4.2 × 10ᙐ4 0.058
ERᙐPRᙐHER2+ 63/5,966 1.31 (0.79–2.16) 0.27 (0.04–1.95) 0.97 (0.64–1.46) 0.88
Combined ERᙐPRᙐHER2ᙐ 3,707/19,728f 1.17 (1.06–1.30) 1.69 (1.43–1.99) 1.25 (1.16–1.34) 1.1 × 10ᙐ9 0.010
ERᙐPRᙐHER2+ 376/18,126 1.15 (0.91–1.46) 1.11 (0.73–1.70) 1.03 (0.88–1.21) 0.71
aNumber of cases and controls with genotype data for rs10069690. All subjects were directly genotyped.
bAdjusted for age, study and principal components in AABC. Adjusted for age and country in TNBCC. Adjusted for age, study and country (EPIC only) in BPC3. Adjusted for age in SEARCH. Combined
results are from the meta-analysis.
c
P for trend (1-d.f.).
d
Excludes San Francisco Bay Area Breast Cancer Study (SFBCS) and Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), as HER2 data were not available.
e
Excludes WHS, as HER2 data were not available.
f
Includes TNBCC. Without TNBCC: 922 ERᙐPRᙐHER2ᙐ cases and 18,126 controls; OR per allele = 1.33 (1.20–1.48), P = 6.3 × 10ᙐ8; heterozygotes: OR = 1.29 (1.09–1.53); homozygotes: OR = 1.85
(1.47–2.33).
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